Search
zavegepant (Zavzpret)
Indications:
- FDA-approved for adults to treat acute migraine with or without aura
Dosage:
- intranasal
Pharmacokinetics:
- rapid onset of action ~15 minutes
Mechanism of action:
- calcitonin gene-related peptide inhibitor
General
calcitonin gene-related peptide (CGRP) inhibitor
References
- Lipton RB, Croop R, Stock DA et al
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute
treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-
controlled multicentre trial.
Lancet Neurol. 2023 Mar;22(3):209-217.
PMID: 36804093